CN102961581A - Thrombolytic drug - Google Patents
Thrombolytic drug Download PDFInfo
- Publication number
- CN102961581A CN102961581A CN2012105189218A CN201210518921A CN102961581A CN 102961581 A CN102961581 A CN 102961581A CN 2012105189218 A CN2012105189218 A CN 2012105189218A CN 201210518921 A CN201210518921 A CN 201210518921A CN 102961581 A CN102961581 A CN 102961581A
- Authority
- CN
- China
- Prior art keywords
- radix
- thrombolytic drug
- rhizoma
- rhizoma atractylodis
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a thrombolytic drug capable of treating thrombotic diseases, and the thrombolytic drug is used for solving the problems of conventional drug for treating thrombotic diseases that the effect is lower, the cost is higher and large side effect is caused. The thrombolytic drug is prepared from the following medicines based on the specific ratio through conventional method of traditional Chinese medicine preparation: astragalus, medicated leaven, radix ophiopogonis, rhizoma alismatis, radix rehmanniae, fructus schisandrae, poria cocos, phellodendron amurense, radix bupleuri, umbellate pore fungus, angelica sinensis, rhizoma atractylodis, orange peel, rhizoma atractylodis macrocephalae, coptis root, cimicifugae foetidae and ginseng. The thrombolytic drug is unique in prescription and reasonable in compatibility of medicines; the medicines act in a synergistic manner; and the thrombolytic drug has the effects of tonifying Qi and replenishing blood, opening channels and collaterals, nourishing heart and tranquilizing mind, is fast in acting, short in treatment course, low in cost, convenient to take, less in side effect and high in cure rate, and realizes more than 90% of total effective rate. The thrombolytic drug is applicable to cerebral thrombosis sequelae, numbness of limbs, facial paralysis and gatism.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be a kind of medicine for the treatment of thrombotic disease, specifically a kind of thrombolytic drug.
Background technology
The day by day change of raising, dietary structure along with living standards of the people, suffering from the thrombotic disease person significantly increases, as: numb limbs and tense tendons, walking disorder, facial hemiparalysis, gatism, cerebral thrombosis and sequela thereof even paralysis etc., this sick life to patient and family members thereof has brought inconvenience and greatly worried, even patient's life is caused greatly threat.At present, although existing some drugs has certain short term effect to the treatment of this disease, curative effect is very low, and therapeutic effect is not satisfactory, and these medicines mostly be Western medicine, and many patients can not adhere to greatly treating because of Western medicine high expensive, side effect.Chinese herbal medicine is the national rarity of China, and developing is traditional Chinese medical science worker's responsibility.Whether can be by the experience of practising medicine for many years, sum up prepare a kind of cheap take Chinese herbal medicine as cost of material, curative effect outstanding, the medicine of several treatment thrombotic disease that have no side effect, the present direction that need to study of traditional Chinese medical science worker exactly.
Summary of the invention
The objective of the invention is for problems such as the medicine that solves existing treatment thrombotic disease exist that curative effect is very low, high expensive, side effect are large, and a kind of thrombolytic drug is provided.
The present invention is achieved by the following technical solutions:
A kind of thrombolytic drug, made by the raw material of following weight fraction:
Radix Astragali 0.7-1.2 Massa Medicata Fermentata 0.5-0.8 Radix Ophiopogonis 0.5-0.8
Rhizoma Alismatis 1.4-1.8 Radix Rehmanniae 0.5-0.8 Fructus Schisandrae Chinensis 0.6-0.9
Poria 0.7-1.2 Cortex Phellodendri 0.22-0.5 Radix Bupleuri 0.22-0.5
Polyporus 0.5-0.8 Radix Angelicae Sinensis 0.5-0.8 Rhizoma Atractylodis 0.8-1.2
Pericarpium Citri tangerinae 0.8-1.2 Rhizoma Atractylodis Macrocephalae 1.4-1.8 Rhizoma Coptidis 0.2-0.5
Rhizoma Cimicifugae 0.8-1.2 Radix Ginseng 0.8-1.2.
Further, the preferred weight umber of described each component raw material is:
Radix Astragali 0.9 Massa Medicata Fermentata 0.8 Radix Ophiopogonis 0.5
Rhizoma Alismatis 1.6 Radix Rehmanniae 0.7 Fructus Schisandrae Chinensis 0.6
Poria 0.9 Cortex Phellodendri 0.5 Radix Bupleuri 0.22
Polyporus 0.6 Radix Angelicae Sinensis 0.8 Rhizoma Atractylodis 0.8
Pericarpium Citri tangerinae 1.0 Rhizoma Atractylodis Macrocephalaes 1.6 Rhizoma Coptidis 0.5
Rhizoma Cimicifugae 1.0 Radix Ginsengs 1.2.
In above-mentioned each raw material, Radix Astragali: have another name called the Radix Astragali, sweet, tepor enters lung, spleen channel, has the effect of inducing diuresis to remove edema, promoting pus discharge and tissue regeneration strengthening, invigorating the spleen and replenishing QI.Massa Medicata Fermentata: bitter, warm, the effect of have strengthening the spleen to promote digestion, regulating QI to expel dampness, inducing sweat.Radix Ophiopogonis: sweet, little hardship, cold, enter lung, stomach, heart channel, have nourishing YIN and moistening the lung, an effect of the relieving restlessness that clears away heart-fire, reinforcing stomach reg fluid.Rhizoma Alismatis: sweet in the mouth, light, cold in nature, return kidney, urinary bladder channel, have promoting diuresis to eliminate damp pathogen, treating stranguria effect expels the heat-evil.Radix Rehmanniae: sweetness and bitterness, cold, enter the heart, liver, kidney channel, have nourishing YIN and clearing away heat, promote the production of body fluid moisturize, effect that removing heat from blood is enriched blood.Fructus Schisandrae Chinensis: temperature, acid, sweet, return lung, the heart, kidney channel, have and astringe the lung, nourishing kidney, promote the production of body fluid, receive the effect of antiperspirant, arresting seminal emission.Poria: the property slightly sweet flavor is flat, enters the heart, lung, spleen channel, has the effect of eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, mind tranquilizing and the heart calming.Cortex Phellodendri: bitter, cold, return kidney, bladder, large intestine channel, have heat clearing and damp drying, eliminating fire and detoxication, except the effect of hectic fever due to YIN-deficiency clearind deficient heat.Radix Bupleuri: cold nature, bitter in the mouth, suffering, return Liver Channel, lung meridian, spleen channel, have that expelling pathogenic factors from the exterior expels the heat-evil, an effect of dispersing the stagnated live-QI to relieve the stagnation of QI, elevate a turnable ladder yang-energy.Polyporus: sweet in the mouth, light, flat, return kidney, urinary bladder channel, have the effect of diuresis eliminating dampness by diuresis, control dysuria, edema, have loose bowels, stranguria with turbid discharge, leukorrhagia.Radix Angelicae Sinensis: Gan Xin, temperature enter the heart, liver, spleen channel, the effect of have benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, rheumatic arthralgia, moisturizing laxation.Rhizoma Atractylodis: it is little sweet, hot, bitter to distinguish the flavor of, and returns spleen, stomach, Liver Channel, has drying damp and strengthening spleen, expelling wind and cold, resolving depression is warded off dirty effect.Pericarpium Citri tangerinae: acrid in the mouth and little hardship, temperature, enter spleen, lung meridian, to have regulate the flow of vital energy transfers, the effect of drying dampness to eliminate phlegm.The Rhizoma Atractylodis Macrocephalae: bitter, sweet, warm, return spleen, stomach warp, have air making-up and spleen enlivening, dampness diuretic, stomach reinforcing and in effect.Rhizoma Coptidis: bitter, cold, nontoxic, GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel have the effect of heat clearing and damp drying, eliminating fire and detoxication, parasite killing.Rhizoma Cimicifugae: hot, little sweet, be slightly cold, return lung, spleen, stomach, large intestine channel, have the effect of the rash of delivering, heat-clearing and toxic substances removing, elevate a turnable ladder yang-energy.Radix Ginseng: property is flat, sweet in the mouth, little hardship, tepor, returns spleen, lung meridian, heart channel, has that strongly invigorating primordial QI, multiple arteries and veins take off admittedly, an effect of invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, the Fructus Alpiniae Oxyphyllae of calming the nerves.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations, for example: these material medicines can be taken by weighing in proportion, pulverizing, entry decoction, filtering residue and make decocting liquid; Perhaps further concentrated liquid medicine is made pill or granule.
The attending scope of medicine of the present invention has: cerebral infarction sequela, numb limbs and tense tendons, facial hemiparalysis, gatism etc.Points for attention: renal insufficiency person, anemia of pregnant woman prohibit clothes.
Pharmaceutical formulation of the present invention is unique, compatibility is reasonable, every drug synergism, have invigorating qi and benefiting blood, get through meridians, the effect of mind tranquilizing and the heart calming, and curative effect is fast, short treating period, with low cost, taking convenience, side effect is little, cure rate is high, the treatment total effective rate can reach more than 90%.Medicine of the present invention is applicable to the diseases such as cerebral infarction sequela, numb limbs and tense tendons, facial hemiparalysis, gatism.
Through 108 patients' treatment situation is added up, male's 56 examples wherein, women's 52 examples, the total treated effect of medicine of the present invention can reach more than 90%.
Model case:
1, Han Zhenxi, the man, 48 years old, people from Ruicheng, Shanxi, having a surplus in the dizziness of readme headache, left side up and down numb limbs and tense tendons in 2 years, is diagnosed as cerebral thrombosis after the examination, so decoction medicine of the present invention: one day twice, sooner or later each is once, continuously decoction after one month above-mentioned symptom extenuate to some extent, continue decoction and fully recover after three months, recur again afterwards.
2, Feng Haibo, the man, 66 years old, Shanxi Feng Lingdu people, slurred speech, facial hemiparalysis, extremity moving obstacle were had a surplus in 3 years, were diagnosed as cerebral infarction after the examination, so decoction medicine of the present invention: one day twice, sooner or later each is once, continuously above-mentioned symptom is extenuated to some extent behind the decoction one and a half months, holds on to fully recover so far recurrence after taking two first quarter moons.
3, Wang Xing, the man, 58 years old, the Yuncheng, Shanxi people, cerebral infarction sequela, extremity moving obstacle, gatism were had a surplus in 1 year, so decoction medicine of the present invention: one day twice, sooner or later each is once, continuous decoction after two months extremity activity is clearly better, and the gatism number of times greatly reduces, and above-mentioned symptom disappears substantially behind the continuation decoction one and a half months.
4, Zhang Yue, woman, 59 years old, the Yuncheng, Shanxi people, suffer from cerebral infarction, left side hemiplegia, unclear, the facial hemiparalysis of language performance, bad through the doctor trained in Western medicine effects of clinic diagnosis, satisfy decoction Drug therapy of the present invention: one day twice, each is once sooner or later, decoction is after one month continuously, and symptom is clearly better, and is flexible before the activity, continue decoction and can walk after two months with descending, be almost recovered.
5, Li Qing, the woman, 48 years old, people from Ruicheng, Shanxi, not straight and numb, the difficulty of walking that cerebral infarction sequela 1 year, left limb bend and stretch, decoction medicine of the present invention: one day twice, sooner or later each is once, continuously decoction after one month above-mentioned symptom be clearly better, continue limbs freedom of movement behind the decoction one and a half months, be almost recovered.
The specific embodiment
Embodiment 1
A kind of thrombolytic drug, make (every part is 1g) by the raw material of following weight fraction:
Radix Astragali 0.9g Massa Medicata Fermentata 0.8g Radix Ophiopogonis 0.5g
Rhizoma Alismatis 1.6g Radix Rehmanniae 0.7g Fructus Schisandrae Chinensis 0.6g
Poria 0.9g Cortex Phellodendri 0.5g Radix Bupleuri 0.22g
Polyporus 0.6g Radix Angelicae Sinensis 0.8g Rhizoma Atractylodis 0.8g
Pericarpium Citri tangerinae 1.0g Rhizoma Atractylodis Macrocephalae 1.6g Rhizoma Coptidis 0.5g
Rhizoma Cimicifugae 1.0g Radix Ginseng 1.2g.
Embodiment 2
A kind of thrombolytic drug, make (every part is 1kg) by the raw material of following weight fraction:
Radix Astragali 0.7kg Massa Medicata Fermentata 0.5kg Radix Ophiopogonis 0.7kg
Rhizoma Alismatis 1.8kg Radix Rehmanniae 0.5kg Fructus Schisandrae Chinensis 0.7kg
Poria 1.2kg Cortex Phellodendri 0.22kg Radix Bupleuri 0.35kg
Polyporus 0.7kg Radix Angelicae Sinensis 0.6kg Rhizoma Atractylodis 1.1kg
Pericarpium Citri tangerinae 0.9kg Rhizoma Atractylodis Macrocephalae 1.8kg Rhizoma Coptidis 0.3kg
Rhizoma Cimicifugae 1.2kg Radix Ginseng 1.0kg.
Embodiment 3
A kind of thrombolytic drug, make (every part is 1 liang) by the raw material of following weight fraction:
0.6 liang of 0.7 liang of Radix Ophiopogonis of 1.1 liang of Massa Medicata Fermentataes of Radix Astragali
0.9 liang of 0.8 liang of Fructus Schisandrae Chinensis of 1.4 liang of Radix Rehmanniae of Rhizoma Alismatis
0.5 liang of 0.3 liang of Radix Bupleuri of 1.0 liang of Cortex Phellodendris of Poria
0.9 liang of 0.5 liang of Rhizoma Atractylodis of 0.5 liang of Radix Angelicae Sinensis of Polyporus
0.4 liang of 1.5 liang of Rhizoma Coptidis of 1.2 liang of Rhizoma Atractylodis Macrocephalaes of Pericarpium Citri tangerinae
1.1 liang of 0.8 liang of Radix Ginsengs of Rhizoma Cimicifugae.
Embodiment 4
A kind of thrombolytic drug, make (every part is 1 gram) by the raw material of following weight fraction:
Radix Astragali 1.2 gram Massa Medicata Fermentataes 0.6 gram Radix Ophiopogonis 0.8 gram
Rhizoma Alismatis 1.7 gram Radix Rehmanniae 0.6 gram Fructus Schisandrae Chinensis 0.8 gram
Poria 0.7 gram Cortex Phellodendri 0.45 gram Radix Bupleuri 0.4 gram
Polyporus 0.8 gram Radix Angelicae Sinensis 0.7 gram Rhizoma Atractylodis 1.2 grams
The Pericarpium Citri tangerinae 0.8 gram Rhizoma Atractylodis Macrocephalae 14 gram Rhizoma Coptidis 0.2 gram
Rhizoma Cimicifugae 0.9 gram Radix Ginseng 0.8 gram.
Claims (2)
1. thrombolytic drug is characterized in that being made by the raw material of following weight fraction:
Radix Astragali 0.7-1.2 Massa Medicata Fermentata 0.5-0.8 Radix Ophiopogonis 0.5-0.8
Rhizoma Alismatis 1.4-1.8 Radix Rehmanniae 0.5-0.8 Fructus Schisandrae Chinensis 0.6-0.9
Poria 0.7-1.2 Cortex Phellodendri 0.22-0.5 Radix Bupleuri 0.22-0.5
Polyporus 0.5-0.8 Radix Angelicae Sinensis 0.5-0.8 Rhizoma Atractylodis 0.8-1.2
Pericarpium Citri tangerinae 0.8-1.2 Rhizoma Atractylodis Macrocephalae 1.4-1.8 Rhizoma Coptidis 0.2-0.5
Rhizoma Cimicifugae 0.8-1.2 Radix Ginseng 0.8-1.2.
2. a kind of thrombolytic drug according to claim 1 is characterized in that being made by the raw material of following weight fraction:
Radix Astragali 0.9 Massa Medicata Fermentata 0.8 Radix Ophiopogonis 0.5
Rhizoma Alismatis 1.6 Radix Rehmanniae 0.7 Fructus Schisandrae Chinensis 0.6
Poria 0.9 Cortex Phellodendri 0.5 Radix Bupleuri 0.22
Polyporus 0.6 Radix Angelicae Sinensis 0.8 Rhizoma Atractylodis 0.8
Pericarpium Citri tangerinae 1.0 Rhizoma Atractylodis Macrocephalaes 1.6 Rhizoma Coptidis 0.5
Rhizoma Cimicifugae 1.0 Radix Ginsengs 1.2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012105189218A CN102961581A (en) | 2012-12-06 | 2012-12-06 | Thrombolytic drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012105189218A CN102961581A (en) | 2012-12-06 | 2012-12-06 | Thrombolytic drug |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102961581A true CN102961581A (en) | 2013-03-13 |
Family
ID=47792200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012105189218A Pending CN102961581A (en) | 2012-12-06 | 2012-12-06 | Thrombolytic drug |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102961581A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108272850A (en) * | 2018-04-25 | 2018-07-13 | 范学祥 | A kind of thrombolytic drug and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101366912A (en) * | 2008-10-07 | 2009-02-18 | 李明 | Oral liquid for children's foot and knee flaccidity |
-
2012
- 2012-12-06 CN CN2012105189218A patent/CN102961581A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101366912A (en) * | 2008-10-07 | 2009-02-18 | 李明 | Oral liquid for children's foot and knee flaccidity |
Non-Patent Citations (1)
Title |
---|
陈文: "生脉散临床运用点滴", 《开卷有益(求医问药)》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108272850A (en) * | 2018-04-25 | 2018-07-13 | 范学祥 | A kind of thrombolytic drug and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721236B (en) | A kind of Chinese medicine composition for the treatment of gastropathy | |
CN103705866A (en) | Traditional Chinese medicine composition for treating hypomenorrhea | |
CN102406911B (en) | Chinese medicine preparation for treating coronary heart disease | |
CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
CN103705682A (en) | Medicine for treating rheumatic lumbago | |
CN101590104A (en) | A kind of Chinese medicine for the treatment of obstructive angiitis | |
CN102988616B (en) | Chinese medicinal composition for treating anemia | |
CN102716409B (en) | Traditional Chinese medicine composition for tonifying qi and nourishing blood | |
CN103479768A (en) | Composite traditional Chinese medicine compound for treating chronic lymphocytic thyroiditis | |
CN101428114B (en) | Medicament for treating chronic hepatitis B, cirrhosis and liver ascites | |
CN102125645B (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
CN105362920A (en) | Chinese proprietary medicine for treating chloasma | |
CN103721082A (en) | Traditional Chinese medicinal composition for treating scapulohumeral periarthritis | |
CN103893724A (en) | Traditional Chinese medicine composition for treating liver depression and spleen deficiency type idiopathic edema of women | |
CN101085247A (en) | Medicine for treating nephritis and uremia and its preparation method | |
CN103083586A (en) | Traditional Chinese medicine for treating gastroptosis | |
CN103550548B (en) | A kind of Chinese medicine composition for the treatment of constipation | |
CN102988632B (en) | Chinese medicinal composition for treating oedematous | |
CN102961581A (en) | Thrombolytic drug | |
CN105288417A (en) | Traditional Chinese medicine for treating infantile malnutrition | |
CN103028063B (en) | Traditional Chinese medicine composition for treating nephropathy | |
CN103751418A (en) | Traditional Chinese medicine composition for treating restless leg syndrome | |
CN102068583B (en) | Chinese medicinal preparation for treating preceded menstrual cycle due to deficiency of vital energy | |
CN103356840A (en) | Medicament for treating cold | |
CN103041021A (en) | Medicine for treatment of senile constipation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130313 |